Medroxyprogesterone acetate and Liver disorder - a phase IV clinical study of FDA data

Summary:

Liver disorder is reported as a side effect among people who take Medroxyprogesterone acetate (medroxyprogesterone acetate), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Provera, and have Diabetes.

The phase IV clinical study analyzes which people have Liver disorder when taking Medroxyprogesterone acetate. It is created by eHealthMe based on reports of 12,407 people who have side effects when taking Medroxyprogesterone acetate from the FDA, and is updated regularly.

What is Medroxyprogesterone acetate?

Medroxyprogesterone acetate has active ingredients of medroxyprogesterone acetate. It is often used in birth control. eHealthMe is studying from 12,600 Medroxyprogesterone acetate users. Check the latest studies of Medroxyprogesterone acetate.

What is Liver disorder?

Liver disorder (liver diseases) is found to be associated with 1,731 drugs and 2,044 conditions by eHealthMe. Check the latest studies of Liver disorder.

On Jul, 13, 2026

12,407 people reported to have side effects when taking Medroxyprogesterone acetate.
Among them, 11 people (0.09%) have Liver disorder.

Could Medroxyprogesterone acetate cause Liver disorder?

Among these 11 people:

How long have people been on Medroxyprogesterone acetate when they have Liver disorder? *

What is the gender of people who have Liver disorder when taking Medroxyprogesterone acetate? *

female: 100 %
male: 0.0 %

What is the age of people who have Liver disorder when taking Medroxyprogesterone acetate? *

What are other drugs people take besides Medroxyprogesterone acetate? *

What are other side effects people have besides Liver disorder? *

Breast Cancer: 7 people, 63.64%
Mitral Valve Sclerosis (thickening and stiffness of the valve): 6 people, 54.55%
Peripheral Coldness: 6 people, 54.55%
Diverticulum (out pouching of a hollow (or a fluid-filled) structure in the body): 6 people, 54.55%
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall): 6 people, 54.55%
Depression: 6 people, 54.55%
Injury: 6 people, 54.55%
Chest Pain: 6 people, 54.55%
Kidney Stones: 6 people, 54.55%
Leukopenia (less number of white blood cells in blood): 6 people, 54.55%

What are the existing conditions these people have? *

Malaria (a parasitic disease due to mosquito bite): 6 people, 54.55%
High Blood Pressure: 6 people, 54.55%
Diabetes: 6 people, 54.55%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 9.09%
Breast Cancer: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Medroxyprogesterone acetate and have Liver disorder?

- Check whether Liver disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Medroxyprogesterone acetate:

Medroxyprogesterone acetate (12,600 reports)

Liver disorder treatments and more:

Liver disorder (57,384 reports)

Browse all side effects of Medroxyprogesterone acetate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Liver disorder:

Liver disorder (1,731 drugs)

Browse all the conditions that are associated with Liver disorder:

Liver disorder (2,044 conditions)

Related publications that referenced our studies

Bahall M, Reyes AJ, Ramcharan K, Hosein N, Seegobin K, Bahall K, Sharma H, Dhansingh S, Mahabir A, "Neuro-ophthalmological manifestations after intramuscular medroxyprogesterone: a forme fruste of idiopathic intracranial hypertension?", Neurology international, 2016 Sep .
Bahall M, Reyes AJ, Ramcharan K, Hosein N, Seegobin K, Bahall K, Sharma H, Dhansingh S, Mahabir A, "Neuro-ophthalmological manifestations after intramuscular medroxyprogesterone: a forme fruste of idiopathic intracranial hypertension?", Neurology international, 2016 Sep .

How the study uses the data?

The study uses data from the FDA. It is based on medroxyprogesterone acetate (the active ingredients of Medroxyprogesterone acetate) and Medroxyprogesterone acetate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.